Phase 1
Completed N=10
Nicotinic Receptors and Schizophrenia
Source: ClinicalTrials.gov NCT00952393 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2016
Primary outcomePrimary: Blood Levels of Drug — 1.5 ng/ml
Summary
The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Levels of Drug |
1.5 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy volunteers: males and females who are incapable of pregnancy
Exclusion Criteria
- Medical illnesses requiring acute treatment
- History of seizures
- Substance abuse including nicotine
Data sourced from ClinicalTrials.gov (NCT00952393). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.